A Phase 2, Open-Label, Multicenter, 2x2 Crossover Trial to Assess the Safety and Efficacy of MS1819-SD in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Phase of Trial: Phase II
Latest Information Update: 18 Feb 2019
At a glance
- Drugs Lipase (Primary)
- Indications Exocrine pancreatic insufficiency
- Focus Adverse reactions; Therapeutic Use
- Acronyms OPTION
- Sponsors AzurRx BioPharma
- 30 Jan 2019 Status changed from not yet recruiting to recruiting.
- 19 Dec 2018 According to the AzurRx BioPharma media release, first site for this trial has been initiated and top-line results from the trial are expected in 2019.
- 16 Nov 2018 Status changed from planning to not yet recruiting.